5.97
price down icon2.45%   -0.15
after-market アフターアワーズ: 6.02 0.05 +0.84%
loading
前日終値:
$6.12
開ける:
$6.22
24時間の取引高:
1.47M
Relative Volume:
0.95
時価総額:
$339.04M
収益:
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.4526
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-3.24%
1か月 パフォーマンス:
-16.74%
6か月 パフォーマンス:
+21.59%
1年 パフォーマンス:
+72.05%
1日の値動き範囲:
Value
$5.97
$6.303
1週間の範囲:
Value
$5.89
$6.62
52週間の値動き範囲:
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
名前
Verastem Inc
Name
セクター
Healthcare (1172)
Name
電話
(781) 292-4200
Name
住所
117 KENDRICK STREET, NEEDHAM, MA
Name
職員
78
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
VSTM's Discussions on Twitter

VSTM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VSTM
Verastem Inc
5.97 339.04M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.44 114.49B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
518.60 52.36B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
298.58 39.81B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
574.96 35.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
262.41 27.94B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-10 開始されました Jefferies Buy
2025-03-24 繰り返されました H.C. Wainwright Buy
2024-12-31 繰り返されました BTIG Research Buy
2024-09-30 開始されました Guggenheim Buy
2023-11-21 再開されました BTIG Research Buy
2023-09-27 開始されました B. Riley Securities Buy
2023-06-15 アップグレード Mizuho Neutral → Buy
2022-09-07 再開されました Alliance Global Partners Buy
2022-04-29 再開されました Cantor Fitzgerald Overweight
2022-04-14 開始されました RBC Capital Mkts Outperform
2022-03-09 開始されました Truist Buy
2021-07-01 開始されました Alliance Global Partners Buy
2021-05-24 アップグレード BTIG Research Neutral → Buy
2019-06-20 ダウングレード BTIG Research Buy → Neutral
2019-05-10 ダウングレード Raymond James Outperform → Mkt Perform
2018-07-13 開始されました BTIG Research Buy
2018-05-02 開始されました Seaport Global Securities Buy
2018-03-08 開始されました B. Riley FBR, Inc. Buy
2017-09-07 繰り返されました H.C. Wainwright Buy
2017-04-13 開始されました Oppenheimer Outperform
2017-03-24 繰り返されました H.C. Wainwright Buy
2015-09-29 ダウングレード Cantor Fitzgerald Buy → Hold
2015-09-29 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 ダウングレード Jefferies Buy → Hold
2015-09-29 ダウングレード Raymond James Strong Buy → Outperform
2015-09-28 ダウングレード Mizuho Buy → Neutral
2015-09-28 ダウングレード ROTH Capital Buy → Neutral
2015-09-09 開始されました Raymond James Strong Buy
2015-05-12 繰り返されました UBS Buy
2015-04-08 開始されました H.C. Wainwright Buy
2015-01-23 繰り返されました ROTH Capital Buy
2014-07-08 再開されました Oppenheimer Perform
2014-02-11 開始されました Mizuho Buy
すべてを表示

Verastem Inc (VSTM) 最新ニュース

pulisher
Jun 10, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 06, 2025

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN

Jun 06, 2025
pulisher
Jun 03, 2025

ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 02, 2025

Transcript : Verastem, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

What's Going On With Verastem Oncology Stock On Monday? - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
May 29, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

May 29, 2025
pulisher
May 28, 2025

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - sharewise

May 28, 2025
pulisher
May 28, 2025

Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire

May 28, 2025
pulisher
May 28, 2025

Verastem stock soars to 52-week high, hits $8.5 By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 27, 2025

Verastem stock soars to 52-week high, hits $8.5 - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

US High Growth Tech Stocks to Watch in May 2025 - simplywall.st

May 27, 2025
pulisher
May 26, 2025

VSTM Up As NDA For Ovarian Cancer Combo Gets FDA's Priority Review Tag - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail

May 24, 2025
pulisher
May 23, 2025

Verastem (VSTM) Stock Price, News & Analysis - MarketBeat

May 23, 2025
pulisher
May 23, 2025

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Verastem Announces Positive RAMP 205 Trial Results - TipRanks

May 23, 2025
pulisher
May 22, 2025

Verastem Oncology Announces Positive Updated Results from RAMP 2 - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Verastem Oncology reports high response in pancreatic cancer trial By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Verastem Oncology reports high response in pancreatic cancer trial - Investing.com

May 22, 2025
pulisher
May 22, 2025

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - FinancialContent

May 22, 2025
pulisher
May 22, 2025

Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges - Investing.com

May 22, 2025
pulisher
May 22, 2025

Verastem Inc (VSTM) Has Recovered 72.4% From Its Low: Is This The Beginning Of A Trend? - Stocksregister

May 22, 2025
pulisher
May 21, 2025

Verastem CFO sells $90,592 in stock By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 20, 2025

Tempus and Verastem partner on ovarian cancer diagnostic test By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 20, 2025

Verastem CFO sells $90,592 in stock - Investing.com

May 20, 2025
pulisher
May 20, 2025

Tempus partners with Verastem for companion diagnostic development - Yahoo Finance

May 20, 2025
pulisher
May 20, 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - 01net

May 20, 2025
pulisher
May 20, 2025

Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment - Stock Titan

May 20, 2025
pulisher
May 20, 2025

The Manufacturers Life Insurance Company Makes New $74,000 Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 20, 2025
pulisher
May 18, 2025

(VSTM) Investment Analysis - news.stocktradersdaily.com

May 18, 2025
pulisher
May 17, 2025

Tower Research Capital LLC TRC Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 17, 2025
pulisher
May 16, 2025

Stifel Financial Corp Grows Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World

May 16, 2025
pulisher
May 16, 2025

11,402 Shares in Verastem, Inc. (NASDAQ:VSTM) Purchased by Voya Investment Management LLC - Defense World

May 16, 2025
pulisher
May 14, 2025

Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verastem: Q1 Earnings Snapshot - Greenwich Time

May 14, 2025
pulisher
May 14, 2025

Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus

May 14, 2025

Verastem Inc (VSTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.63
price down icon 0.92%
$97.98
price up icon 7.75%
$34.05
price up icon 1.40%
$19.58
price down icon 11.32%
$105.46
price down icon 1.34%
biotechnology ONC
$262.41
price down icon 0.38%
大文字化:     |  ボリューム (24 時間):